Indications for Lenvatinib mesylate

Lenvatinib is suitable for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC); combined with pembrolizumab is suitable for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC); combined with everolimus is suitable for adult patients with advanced renal cell carcinoma who have previously received one anti-angiogenic treatment. Lenvatinib is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) and is also indicated in combination with pembrolizumab for the treatment of patients with advanced endometrial cancer (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), who in any case have disease progression after prior systemic therapy and are not candidates for therapeutic surgery or radiotherapy.